Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 176,423
  • Shares Outstanding, K 70,569
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,500 K
  • EBIT $ -128 M
  • EBITDA $ -132 M
  • 60-Month Beta 0.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.41

Options Overview Details

View History
  • Implied Volatility 75.04% ( -5.42%)
  • Historical Volatility 77.54%
  • IV Percentile 6%
  • IV Rank 9.66%
  • IV High 398.53% on 10/31/24
  • IV Low 40.45% on 06/11/24
  • Put/Call Vol Ratio 1.68
  • Today's Volume 161
  • Volume Avg (30-Day) 285
  • Put/Call OI Ratio 3.78
  • Today's Open Interest 5,213
  • Open Int (30-Day) 3,391

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 5
  • High Estimate -0.36
  • Low Estimate -0.43
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +29.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.38 +3.57%
on 11/19/24
4.22 -41.59%
on 10/22/24
-1.75 (-41.59%)
since 10/21/24
3-Month
2.38 +3.57%
on 11/19/24
6.63 -62.81%
on 09/10/24
-2.92 (-54.18%)
since 08/21/24
52-Week
2.38 +3.57%
on 11/19/24
16.24 -84.82%
on 03/07/24
-0.07 (-2.57%)
since 11/21/23

Most Recent Stories

More News
Nkarta to Participate in an Upcoming Investor Conference

NKTX : 2.48 (-0.80%)
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

NKTX : 2.48 (-0.80%)
Why Nkarta Stock Is Soaring Today

One analyst is now more bullish about this clinical-stage biotech stock.

RJF : 164.36 (+1.34%)
NKTX : 2.48 (-0.80%)
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 0.9800 (-1.85%)
ONC.TO : 1.38 (-1.43%)
AMGN : 288.10 (+0.08%)
AMAM : 28.00 (+0.07%)
ELEV : 0.5969 (+2.72%)
NKTX : 2.48 (-0.80%)
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

/PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq:...

NKTX : 2.48 (-0.80%)
Why Shares of Nkarta Are Slumping Tuesday

The pharmaceutical stock dropped after announcing so-so clinical trial results.

CRSP : 46.08 (-2.50%)
NKTX : 2.48 (-0.80%)
Nkarta Announces Key Senior Leadership Team Appointments

Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to...

NKTX : 2.48 (-0.80%)
Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

NKTX : 2.48 (-0.80%)
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing...

NKTX : 2.48 (-0.80%)
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of...

NKTX : 2.48 (-0.80%)

Business Summary

Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.

See More

Key Turning Points

3rd Resistance Point 2.70
2nd Resistance Point 2.62
1st Resistance Point 2.56
Last Price 2.48
1st Support Level 2.42
2nd Support Level 2.34
3rd Support Level 2.28

See More

52-Week High 16.24
Fibonacci 61.8% 10.95
Fibonacci 50% 9.31
Fibonacci 38.2% 7.67
Last Price 2.48
52-Week Low 2.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar